Details
Stereochemistry | ACHIRAL |
Molecular Formula | C6H5O7.3C5H14NO |
Molecular Weight | 501.612 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C[N+](C)(C)CCO.C[N+](C)(C)CCO.C[N+](C)(C)CCO.OC(CC([O-])=O)(CC([O-])=O)C([O-])=O
InChI
InChIKey=RPERJPYDELTDMR-UHFFFAOYSA-K
InChI=1S/C6H8O7.3C5H14NO/c7-3(8)1-6(13,5(11)12)2-4(9)10;3*1-6(2,3)4-5-7/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);3*7H,4-5H2,1-3H3/q;3*+1/p-3
TRICHOLINE CITRATE is indicated for the treatment and management of hepatic disorders and asthma symptoms in adults. It exerts lipotropic action in the hepatic cells. It also can lower the symptoms of asthma and reducing the pro-inflammatory and inflammatory mediators of the leukotriene pathway.
Approval Year
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Cypron Approved UseCyproheptadine Tricholine Citrate & Sorbitol Syrup is used for the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms:
· Occasional Constipation
· Liver Disorders
· Asthma Symptoms In Adults
· Allergic Reactions
· Seasonal Allergies
· Mild And Uncomplicated Hives |
|||
Primary | Cypron Approved UseCyproheptadine Tricholine Citrate & Sorbitol Syrup is used for the treatment, control, prevention, & improvement of the following diseases, conditions and symptoms:
· Occasional Constipation
· Liver Disorders
· Asthma Symptoms In Adults
· Allergic Reactions
· Seasonal Allergies
· Mild And Uncomplicated Hives |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
moderate | ||||
moderate | ||||
moderate | ||||
no [Activation >10 uM] | ||||
no [Activation >10 uM] | ||||
no [Activation >10 uM] | ||||
no [Activation >10 uM] | ||||
no [Activation >10 uM] | ||||
no | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
yes [Km 102 uM] | ||||
yes |
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
11024
Created by
admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
|
PRIMARY | |||
|
2453
Created by
admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
|
PRIMARY | RxNorm | ||
|
208-907-5
Created by
admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
|
PRIMARY | |||
|
546-63-4
Created by
admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
|
PRIMARY | |||
|
DTXSID5060273
Created by
admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
|
PRIMARY | |||
|
EH8N140TJ7
Created by
admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
|
PRIMARY | |||
|
100000080101
Created by
admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
|
PRIMARY | |||
|
SUB13351MIG
Created by
admin on Fri Dec 15 15:02:49 GMT 2023 , Edited by admin on Fri Dec 15 15:02:49 GMT 2023
|
PRIMARY |
PARENT (SALT/SOLVATE)
PARENT (SALT/SOLVATE)
SUBSTANCE RECORD